-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $47

Benzinga·08/01/2025 20:19:04
Listen to the news
Citigroup analyst Andrew Baum maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $51 to $47.